Not Open Access | Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ Vaccine in Tanzanian adults
Reference:
Clin Infect Dis. 2019 Nov 29. pii: ciz1152
A vaccine would be an ideal tool for reducing malaria’s impact. PfSPZ Vaccine (radiation attenuated, aseptic, purified, cryopreserved Plasmodium falciparum [Pf] sporozoites [SPZ]) has been well tolerated and safe in >1,526 malaria-naïve and experienced 6-month to 65-year-olds in the U.S., Europe, and Africa. When vaccine efficacy (VE) of 5 doses of 2.7x105 PfSPZ of PfSPZ Vaccine was assessed in adults against controlled human malaria infection (CHMI) in the U.S. and Tanzania and intense field transmission of heterogeneous Pf in Mali, Tanzanians had the lowest VE (20%).
Country:
